This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lafleur, E. A. Articles by Kleinerman, E. S. Search for Related Content PubMed PubMed Citation Articles by Lafleur, E. A. Articles by Kleinerman, E. S.

Interleukin (IL)-12 and IL-12 Gene Transfer Up-Regulate Fas Expression in Human Osteosarcoma and Breast Cancer Cells¹

Departments of Cancer Biology [E. A. L., S-F. J., Z. Z., E. S. K.], Pediatrics [L. L. W., E. S. K.], and Immunology [L. B. O-S.], The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030

Expression of Fas (CD95, APO-1), a cell surface receptor capable of inducing ligand-mediated apoptosis, is involved in tissue homeostasis and elimination of targeted cells by natural killer and T cells. Corruption of this pathway, such as reduced Fas expression, can allow tumor cells to escape elimination and promote metastatic potential. In this study, the status of Fas expression has been examined in the parental SAOS human osteosarcoma cells that do not metastasize and in selected variants that cause lung metastases in 16 weeks (LM2) or 8 weeks (LM6) after i.v. injection into nude mice. Fas expression correlated with the metastatic potentials of the three cell lines. Northern and fluorescence-activated cell-sorting analyses indicated that LM6 cells expressed Fas at a lower level than seen in the parental cells. Infection of the LM6 cells with an adenoviral vector containing the murine interleukin (IL)-12 gene (Ad.mIL-12) or treatment with recombinant murine IL-12 resulted in a dose-dependent up-regulation of Fas. The up-regulation of Fas by IL-12 was also demonstrated in human etoposide-resistant MDA-MB-231 breast cancer cells. [³H]Thymidine growth inhibition studies indicated that the cell surface Fas induced after IL-12 exposure was functional and able to mediate cell death on cross-linking with anti-Fas. We also demonstrate that this effect is independent of IFN-. Whereas these cell lines are sensitive to IFN-, incubation with IFN- does not increase susceptibility to Fas-mediated cell death, nor do these cells produce IFN- with or without IL-12 treatment. We hypothesize that expression of Fas may play a role in the elimination of metastatic tumor cells in the lung, an organ in which Fas ligand is expressed. The antitumor activity of IL-12 may be secondary in part to its ability to up-regulate Fas expression on tumor cells, which subsequently increases immune-mediated destruction of osteosarcoma cells.

This article has been cited by other articles:

				N. Gordon, N. V. Koshkina, S.-F. Jia, C. Khanna, A. Mendoza, L. L. Worth, and E. S. Kleinerman Corruption of the Fas Pathway Delays the Pulmonary Clearance of Murine Osteosarcoma Cells, Enhances Their Metastatic Potential, and Reduces the Effect of Aerosol Gemcitabine Clin. Cancer Res., August 1, 2007; 13(15): 4503 - 4510. [Abstract] [Full Text] [PDF]

				M. N. Torrero, X. Xia, W. Henk, S. Yu, and S. Li Stat1 deficiency in the host enhances interleukin-12-mediated tumor regression. Cancer Res., April 15, 2006; 66(8): 4461 - 4467. [Abstract] [Full Text] [PDF]

				Z. Zhou, E. A. Lafleur, N. V. Koshkina, L. L. Worth, M. S. Lester, and E. S. Kleinerman Interleukin-12 Up-Regulates Fas Expression in Human Osteosarcoma and Ewing's Sarcoma Cells by Enhancing Its Promoter Activity Mol. Cancer Res., December 1, 2005; 3(12): 685 - 692. [Abstract] [Full Text] [PDF]

				P. A. Meyers, C. L. Schwartz, M. Krailo, E. S. Kleinerman, D. Betcher, M. L. Bernstein, E. Conrad, W. Ferguson, M. Gebhardt, A. M. Goorin, et al. Osteosarcoma: A Randomized, Prospective Trial of the Addition of Ifosfamide and/or Muramyl Tripeptide to Cisplatin, Doxorubicin, and High-Dose Methotrexate J. Clin. Oncol., March 20, 2005; 23(9): 2004 - 2011. [Abstract] [Full Text] [PDF]

				E. A. Lafleur, N. V. Koshkina, J. Stewart, S.-F. Jia, L. L. Worth, X. Duan, and E. S. Kleinerman Increased Fas Expression Reduces the Metastatic Potential of Human Osteosarcoma Cells Clin. Cancer Res., December 1, 2004; 10(23): 8114 - 8119. [Abstract] [Full Text] [PDF]

				X. Duan, Z. Zhou, S.-F. Jia, M. Colvin, E. A. Lafleur, and E. S. Kleinerman Interleukin-12 Enhances the Sensitivity of Human Osteosarcoma Cells to 4-Hydroperoxycyclophosphamide by a Mechanism Involving the Fas/Fas-Ligand Pathway Clin. Cancer Res., January 15, 2004; 10(2): 777 - 783. [Abstract] [Full Text] [PDF]

				R. Gorlick, P. Anderson, I. Andrulis, C. Arndt, G. P. Beardsley, M. Bernstein, J. Bridge, N.-K. Cheung, J. S. Dome, D. Ebb, et al. Biology of Childhood Osteogenic Sarcoma and Potential Targets for Therapeutic Development: Meeting Summary Clin. Cancer Res., November 15, 2003; 9(15): 5442 - 5453. [Abstract] [Full Text] [PDF]

				M. A. Sheard, S. Uldrijan, and B. Vojtesek Role of p53 in Regulating Constitutive and X-Radiation-Inducible CD95 Expression and Function in Carcinoma Cells Cancer Res., November 1, 2003; 63(21): 7176 - 7184. [Abstract] [Full Text] [PDF]

				H. Kitaura, N. Nagata, Y. Fujimura, H. Hotokezaka, N. Yoshida, and K. Nakayama Effect of IL-12 on TNF-{alpha}-Mediated Osteoclast Formation in Bone Marrow Cells: Apoptosis Mediated by Fas/Fas Ligand Interaction J. Immunol., November 1, 2002; 169(9): 4732 - 4738. [Abstract] [Full Text] [PDF]